1. Medtech Insight
  2. >>Business
  3. >>Startups & SMEs

CyberHeart Takes Non-invasive Approach To AF Ablation

 
• By Jenny Blair

CyberHeart Inc. is developing a non-invasive approach to cardiac dysrhythmia ablation by adapting technology from CyberKnife, the radiosurgery system for cancer treatment. Current clinical trials are examining the use of CyberHeart not only for atrial fibrillation (AF) treatment, but also for ventricular tachycardia, for which a US pivotal trial is scheduled for early 2017.

Catheter-based atrial fibrillation (AF) ablation procedures have spared countless patients from open-heart surgery, and companies continue to improve on that technology. ([A#MT103609]) But an entirely non-invasive ablation option could soon be available. CyberHeart Inc. is developing a non-invasive approach to cardiac dysrhythmia ablation by adapting technology from CyberKnife, the radiosurgery system for cancer treatment. The treatment requires no anesthesia, and patients go home the same day.

Patrick Maguire, MD, PhD, a cardiac surgeon who once performed open AF ablation or maze procedures, is president and CEO of the company, which was founded in 2005. AF is...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Startups & SMEs

First AI Breast Cancer Prediction Platform Receives FDA Authorization

 
• By Natasha Barrow

Clairity’s "first-in-class" mammography-based AI screening tool, Clairity Breast, provides "equitable risk assessments," expanding access to lifesaving early detection for breast cancer, said company founder Connie Lehman.

SAGA Diagnostics Launches Early Breast Cancer MRD Detection Test In US

 
• By Natasha Barrow

SAGA Diagnostics has launched its breast cancer residual and recurrence detection test – Pathlight – in the US. The test’s ultrahigh sensitivity and specificity is rare to see in oncology, the company claimed.

ConcertAI Launches Generative AI-Powered Precision Suite

 
• By Natasha Barrow

Valued at over $1.9bn, ConcertAI is building on its pre-existing multi-agentic AI SaaS solution CARAai to bring life science customers the new Precision suite of applications: Precision Explorer, Precision Trials, Precision GTM and Precision360.

Bone Surgery Startup Surgify Medical Raises $7.9m

 
• By Natasha Barrow

Surgify Medical’s selective drill tip, Surgify Halo, is “an obvious choice for surgeons,” said Boris Hofmann, head of ZEISS Ventures and lead investor in the company’s series A funding round.

More from Business

Siemens Healthineers Widens FY25 EPS Range By €0.15 To Absorb Up To €300M In Tariff Costs

 
• By Shubham Singh

The imaging, Varian, and advanced therapies segments – which are more reliant on equipment sales – are more heavily affected, with tariffs applying to roughly 55% of their revenue base. In diagnostics, the company expects minimal exposure due to sufficient US value-added manufacturing.

Cardiosense Advances Noninvasive Heart Monitoring With Final Validation Study

 
• By Marion Webb

Cardiosense has launched a nationwide clinical study, SEISMIC-HF II, to validate its non-invasive, AI-powered technology for monitoring heart failure. The data will be used to file for US regulatory clearance of the Cardiosense heart failure monitoring platform.

ConcertAI Launches Generative AI-Powered Precision Suite

 
• By Natasha Barrow

Valued at over $1.9bn, ConcertAI is building on its pre-existing multi-agentic AI SaaS solution CARAai to bring life science customers the new Precision suite of applications: Precision Explorer, Precision Trials, Precision GTM and Precision360.